The FDA approved irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin as a first-line regimen for the management of patients with metastatic pancreatic adenocarcinoma.
The FDA approved pirtobrutinib for adults with either chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy.
The US Food and Drug Administration has expanded the approval of Faslodex, a hormonal therapy for the treatment of breast cancer first approved in 2002.
The US Food and Drug Administration has approved a new option for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
